Cowen Starts CRISPR Therapeutics (CRSP) at Market Perform
Tweet Send to a Friend
Cowen analyst Tyler Van Buren initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Market Perform rating.The analyst commented, "CRISPR's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
